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Dear Editor 
Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a 
prevalence of 18% in Europe1.  The pathogenesis of PLE appears to involve delayed cell mediated 
hypersensitivity and aberrant Langerhans cell function2,3.  Phototherapy, using narrowband UVB 
(UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic 
desensitisation in PLE, with benefit experienced in 90% of patients4,5.  The mechanism of 
desensitisation is poorly understood but that stratum corneum thickening, induction of 
immunomodulatory cytokines and changes in Langerhans cells and dermal mast cells may be 
implicated.6,7  
We describe five years’ experience (2008-2013) of phototherapeutic desensitisation for PLE.  
Patients with suspected photosensitivity (n=1475) referred to the Scottish Photobiology Service, 
based at the Photobiology Unit, Ninewells Hospital and Medical School, Dundee, underwent 
investigations (including monochromator phototesting across the solar spectrum, UVA provocation 
testing, narrowband UVB minimal erythema dose (MED) testing and lupus serology).  Of these 1475 
patients, 370 (25%) were diagnosed with PLE.  Of these 370 patients, phototherapeutic 
desensitisation was offered to 109 and local Tayside case notes were available for review in 79 of 
these patients (76 UVB and 3 UVA1).  Treatment numbers, occurrence of provoked PLE, and 
response, as defined by use of repeat treatment courses in subsequent years, were recorded. 
The standard regimens used were: 
Narrowband UVB phototherapy (or UVA1) three times a week (50% MED starting dose and 20% dose 
increments each treatment, unless erythema or PLE induced, in which case increments were 
reduced to 10% after erythema or PLE settled) for 15 treatments; PUVA (oral 8-methoxypsoralen 
25mg/m2) twice-weekly for 15 treatments (70% minimal phototoxic dose (MPD) starting dose and 
40%, reducing to 20% if erythema or PLE, dose increments at each treatment).  If PLE was provoked, 
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topical betamethasone valerate 0.1% ointment/cream was prescribed and treatment adjusted as 
described above. 
For the first course of desensitisation 46 patients (59%) received photo-exposed site treatment and 
32 (41%) received whole body exposure (data missing for one patient).  Following each treatment 
course patients were encouraged to cautiously seek top-up sunlight exposure to maintain 
desensitisation.  Patients were followed up in autumn and, if deemed successful, the treatment was 
repeated yearly in spring.  For patients who failed to obtain adequate desensitisation after two 
consecutive years of UVB, PUVA was offered.   
Of the 79 patients with PLE who underwent desensitisation, 67 were female; 12 male (median age 
41 (range 12-69) years).  Fitzpatrick skin phototypes were: I (n=18), II (n=42), III (n=16) and IV (n=3).  
Twenty eight patients had been investigated using monochromator phototesting, with normal 
responses in 27 (96%).  The patient with abnormal responses showed borderline UVA and visible 
light photosensitivity.  Eight of the 15 patients (53%) who underwent provocation testing had 
abnormal erythemal and/or papular broadband UVA reactions. 
Seventy six patients (96%) received narrowband UVB.  The median UVB MED was 0.147 (range 
0.048-0.4) J/cm2.  The median starting dose was 0.07 (range 0.02-0.2) J/cm2.  
Of those patients who received UVB phototherapy: 52 (68%) completed 15 treatments; 11 (14%) 
received 10 to 14 treatments; 7 (9%) had less than 10 treatments and 6 (8%) received more than 15 
exposures (median 15 range (1-33) (Figure 1).  Of those who did not complete 15 treatments: 1 
patient stopped after the first treatment as it provoked severe PLE, 1 patient stopped as she was 
diagnosed with chronic fatigue, 3 patients failed to attend  (data missing for 2).  Those who 
underwent 10 – 14 treatments deemed this to be satisfactory and did not complete 15 sessions.  The 
maximum number of treatments was 33, in a patient with co-existing chronic idiopathic urticaria.  Of 
the 58 patients (76%) who completed 15 or more treatments, 37 (64%) had a second course the 
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following year.  Sixteen patients (28%) had three or more UVB courses in this five-year period (Figure 
2).  Thus, 53 of the 58 patients (91%) who completed at least 15 treatments had a successful 
treatment outcome, as defined by going on to have further courses in subsequent years, indicative 
of efficacy and suitability of treatment.   
Four of the patients who received UVB went on to have either PUVA (n=2) or UVA1 (n=2) after failing 
to respond to two consecutive annual courses of UVB.  Of these, two patients successfully received 
PUVA for two consecutive years and one of the patients who received UVA1 went on to have a 
second course the following year (Figure 2).  
Three patients underwent a primary course of UVA1 desensitisation, having failed UVB 
phototherapy in previous years: all 3 completed 15 or more treatments and subsequent treatment 
courses were planned for the following year for all three patients (Figure 1).  
Of the 79 patients who underwent desensitisation 44, (56%) had provoked PLE during treatment and 
one patient receiving UVB developed herpes simplex labialis.  PLE induction was most likely to occur 
at treatment eight (median 8 (range 1-14)).  The increments were reduced to 10% for all patients 
who developed PLE and 22 (50%) required a topical corticosteroid. Systemic steroids were not 
required.  Of the eight patients who had a positive abnormal erythemal and/or papular reaction on 
UVA provocation testing, 7 (88%) had PLE induced during treatment, whereas of the 7 who had a 
negative provocation test, only 3 developed PLE during treatment; (50%; data missing from one). 
Discussion 
We have confirmed that phototherapeutic desensitisation can be effective for PLE. In a randomized, 
controlled comparative study of narrowband UVB with PUVA in 25 patients with PLE, equivalent 
efﬁcacy was shown4.  However, UVB is almost invariably the treatment of choice, given the need for 
psoralen and proven photocarcinogenic risk with PUVA and the lack of reported cancer risk with UVB 
to date8.  Certainly, in our study 96% of patients received narrowband UVB.  
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Although PLE is commonly provoked during treatment (56% in this case series), our review suggests 
this occurs most commonly at the eighth treatment session which can thus help to plan ahead and 
advise patients accordingly.  It is not known whether prophylactic use of topical corticosteroid 
during week three of treatment may limit the frequency of this adverse effect.  Indeed, further 
studies are warranted to investigate this or the role of other potential suppressive therapies, such as 
Polypodium Leucotomas.  Treatment is usually well tolerated and patients are able to complete a 
treatment course, with dose increment reductions and topical corticosteroid use.  In our experience, 
those patients who, on investigation, had PLE induced on UVA provocation testing, are most at risk 
of developing PLE during treatment.  Of the patients with abnormal erythemal and/or papular 
broadband UVA provocation test site reactions, 88% had provocation of PLE during treatment, 
indicating that if this investigation is positive then patients can be advised that it is very likely that 
they will develop PLE during desensitisation therapy.  The patients that we included in this review 
were those who had been referred to the SPS and, as such, represent the more severe/most 
troublesome end of the spectrum of PLE, as only the minority of patients with PLE will be formally 
phototested. However, with this caveat, the group of patients with positive photoprovocation tests 
would be the most suitable to target with adjuvant prophylactic or concurrent topical glucocorticoid 
or other suppressive therapy and, as highlighted above, this merits further study. 
Most patients received treatment to photo-exposed sites only (59%), and although PLE was 
provoked in 56% of patients during desensitisation, this figure may have been  higher if whole body 
irradiation had been used in all patients5.  
The photoprotective effects of UVA and PUVA are temporary and need to be repeated.  Fifty-eight 
patients completed fifteen or more UVB treatments (76%) and, as defined by going on to repeat 
treatment courses in subsequent years, 91% of these subjects found treatment to be effective, with 
no apparent loss of efficacy with subsequent courses.  We commonly advise patients who have had 
three or four years of successful desensitisation to try a year without treatment.  
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Our review demonstrates that phototherapeutic desensitisation for PLE, predominantly with UVB, is 
safe, generally well tolerated and effective.  These data provide us with practical information and 
guidance with respect to risk of PLE induction during a treatment course and the most likely time for 
this to develop, which is informative for patients embarking on desensitisation phototherapy.  
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Figure 1 
 
 Patients who underwent photoinvestigation (2008-2013) (n=1475)  
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Figure 2 
 
  
 
Patients who had a primary course of 15 or more UVB treatments 
during the 5 year period (n=58) 
 
 
 
Patients who had a second course (n=37) 
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more courses (n=16) 
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UVA1 (n=2) 
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Second course of UVA1 
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Legends 
Figure 1. Flowchart showing the number of patients undergoing the different desensitisation 
modalities 
Figure 2. Flowchart showing the subsequent treatment course after a primary course of UVB (15 or 
more treatments) 
 
